{"protocolSection": {"identificationModule": {"nctId": "NCT01111110", "orgStudyIdInfo": {"id": "IRB 103-2008"}, "secondaryIdInfos": [{"id": "Children's Miracle Network UFl", "type": "OTHER_GRANT", "domain": "Children's Miracle Network, University of Florida"}], "organization": {"fullName": "University of Florida", "class": "OTHER"}, "briefTitle": "Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm", "officialTitle": "Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-05"}, "primaryCompletionDateStruct": {"date": "2009-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-04-23", "studyFirstSubmitQcDate": "2010-04-26", "studyFirstPostDateStruct": {"date": "2010-04-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-01-10", "resultsFirstSubmitQcDate": "2012-05-14", "resultsFirstPostDateStruct": {"date": "2012-06-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-02-03", "lastUpdatePostDateStruct": {"date": "2022-02-28", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Florida", "class": "OTHER"}, "collaborators": [{"name": "Children's Miracle Network", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Delivery of HFA albuterol through an antistatic valved holding chamber (VHC) will improve bronchodilator response during nocturnal bronchospasm."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 88, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Anti-static then Static for Albuterol", "type": "EXPERIMENTAL", "description": "albuterol anti-static first then static chamber second.", "interventionNames": ["Device: anti-static then static"]}, {"label": "Static then Anti-static for Albuterol", "type": "EXPERIMENTAL", "description": "static then antistatic albuterol", "interventionNames": ["Device: Static then anti-static chamber"]}], "interventions": [{"type": "DEVICE", "name": "anti-static then static", "description": "Albuterol using static chambers", "armGroupLabels": ["Anti-static then Static for Albuterol"]}, {"type": "DEVICE", "name": "Static then anti-static chamber", "description": "albuterol with Static then anti-static chambers", "armGroupLabels": ["Static then Anti-static for Albuterol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Y=100([FEV1 at 1 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1.", "description": "(Percent improvement in FEV1 (Forced Expiratory Volume and Forced Vital Capacity) Post Dose for Period 2 over 4AM Baseline value) less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 1 Puff go into chamber", "timeFrame": "fifteen minutes after 1 puff of albuterol"}, {"measure": "Y=100([FEV1 at 2 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1.", "description": "(Percent improvement in FEV1(Forced Expiratory Volume and Forced Vital Capacity) Post Dose for Period 2 over 4AM Baseline value) less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 2 Puffs go into chamber", "timeFrame": "15 minutes after 2 puffs of albuterol"}, {"measure": "Y=100([FEV1 at 4 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1.", "description": "(Percent improvement in FEV1 (Forced Expiratory Volume and Forced Vital Capacity) Post Dose for Period 2 over 4AM Baseline value)less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 4 Puffs go into chamber", "timeFrame": "fifteen minutes after 4 puffs of albuterol"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-65 years.\n* Physician diagnosis of asthma.\n* FEV1 60-80% predicted during the day.\n* FEV1 increases \u2265 12 % and to \u2265 80% predicted after 2- 4 puffs of albuterol HFA MDI delivered by antistatic VHC.\n* No smoking in the previous year and \\< 10-pack year history.\n* No history of severe asthma attacks requiring ER visit or hospitalization in the previous three months.\n\nExclusion Criteria:\n\n* Patient required a short course of oral steroid in the past 30 days.\n* Any disease that is inadequately controlled or any medication that would worsen asthma or interact with asthma medications.\n* History of viral respiratory tract infection in the 3 weeks prior to the screening visit.\n* Positive pregnancy test.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32610", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects qualified in the screening visit went into a 7 day run-in-period They needed to have a 20% peak flow overnight drop on 3/7 nights in order to qualify for overnight stays in the Clinical Research Center. Arms are identified by order of treatment assignment. Any other designation is not consistent with our protocol requirements.", "recruitmentDetails": "Recruitment process was done in the Asthma Research Lab. Note that 88 were screened and 4 subjects randomized but determined to be ineligile before starting treatment. They are amongst the screen failures.", "groups": [{"id": "FG000", "title": "Anti-static/Static", "description": "albuterol with anti-static chamber then Static on another night"}, {"id": "FG001", "title": "Static/Antistatic", "description": "albuterol with static chamber then with antistatic chamber on another night."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Anti-static/Static", "description": "albuterol with anti-static chamber then Static on another night"}, {"id": "BG001", "title": "Static/Antistatic", "description": "albuterol with static chamber then with antistatic chamber on another night."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "28.3", "spread": "11.1"}, {"groupId": "BG001", "value": "21.5", "spread": "2.8"}, {"groupId": "BG002", "value": "24.4", "spread": "7.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Y=100([FEV1 at 1 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1.", "description": "(Percent improvement in FEV1 (Forced Expiratory Volume and Forced Vital Capacity) Post Dose for Period 2 over 4AM Baseline value) less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 1 Puff go into chamber", "populationDescription": "Study intended to get more subjects, but PI's review committee had to deal with candidate deadlines and a high rate of screen failures and allowed her to test seven subjects. Primary concern was the research experience, not the study questions. There was no bias in failing to meet accrual objectives thanks to the blinding.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percentage of change from 4AM", "timeFrame": "fifteen minutes after 1 puff of albuterol", "groups": [{"id": "OG000", "title": "Anti-static/Static", "description": "albuterol with anti-static chamber then Static on another night"}, {"id": "OG001", "title": "Static/Antistatic", "description": "albuterol with static chamber then with antistatic chamber on another night."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.4", "spread": "12.2"}, {"groupId": "OG001", "value": "26.7", "spread": "20.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "(Comparison of period 2 minus period 1) results Point and interval estimates are halved because this estimates twice the effect size.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.026", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "two sample effect size must be halved to account for mean difference estimates twice the effect size", "paramType": "half the mean difference", "paramValue": "21.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.8", "ciUpperLimit": "41.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.7", "estimateComment": "See 4 Puff result"}]}, {"type": "PRIMARY", "title": "Y=100([FEV1 at 2 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1.", "description": "(Percent improvement in FEV1(Forced Expiratory Volume and Forced Vital Capacity) Post Dose for Period 2 over 4AM Baseline value) less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 2 Puffs go into chamber", "populationDescription": "Study intended to get more subjects, but PI's review committee had to deal with candidate deadlines and a high rate of screen failures and allowed her to test seven subjects. Primary concern was the research experience, not the study questions. There was no bias in failing to meet accrual objectives thanks to the blinding.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of change from 4AM", "timeFrame": "15 minutes after 2 puffs of albuterol", "groups": [{"id": "OG000", "title": "Anti-static/Static", "description": "albuterol with anti-static chamber then Static on another night"}, {"id": "OG001", "title": "Static/Antistatic", "description": "albuterol with static chamber then with antistatic chamber on another night."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.3", "spread": "14.1"}, {"groupId": "OG001", "value": "31.8", "spread": "19.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Study intended to get more subjects, but PI's review committee had to deal with candidate deadlines and a high rate of screen failures and allowed her to test seven subjects. Primary concern was the research experience, not the study questions. There was no bias in failing to meet accrual objectives thanks to the blinding.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.018", "pValueComment": "The effect size is half the difference between the means as (A-B)-(B-A)=2A-2B", "statisticalMethod": "t-test, 2 sided", "statisticalComment": "Must take half the mean difference to estimate effect size", "paramType": "half the mean difference", "paramValue": "23.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.0", "ciUpperLimit": "41.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.8", "estimateComment": "No comments"}]}, {"type": "PRIMARY", "title": "Y=100([FEV1 at 4 Puffs-FEV1 at 4AM)/FEV1@4AM] Difference Period 2 Minus Period 1.", "description": "(Percent improvement in FEV1 (Forced Expiratory Volume and Forced Vital Capacity) Post Dose for Period 2 over 4AM Baseline value)less (Percent improvement in FEV1 Post Dose for Period 1 over 4AM Baseline value) when 4 Puffs go into chamber", "populationDescription": "Study intended to get more subjects, but PI's review committee had to deal with candidate deadlines and a high rate of screen failures and allowed her to test seven subjects. Primary concern was the research experience, not the study questions. There was no bias in failing to meet accrual objectives thanks to the blinding.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of change from 4AM", "timeFrame": "fifteen minutes after 4 puffs of albuterol", "groups": [{"id": "OG000", "title": "Anti-static/Static", "description": "albuterol with anti-static chamber then Static on another night"}, {"id": "OG001", "title": "Static/Antistatic", "description": "albuterol with static chamber then with antistatic chamber on another night."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-17.5", "spread": "13.6"}, {"groupId": "OG001", "value": "31.9", "spread": "19.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis is that the Treatment order is independent of the dependent variable based on Period 2 minus Period 1", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.013", "statisticalMethod": "t-test, 2 sided", "paramType": "Effect size=half the mean diff", "paramValue": "24.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "7.7", "ciUpperLimit": "41.7", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "6.6", "estimateComment": "You kicked this out on another trial, but note that the period 2-Period 1 differences between the orderings estimate twice the effect size. The effect sizes herein take this into account."}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Static", "description": "albuterol with static chamber", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 0, "otherNumAtRisk": 7}, {"id": "EG001", "title": "Antistatic", "description": "albuterol with antistatic chamber.", "seriousNumAffected": 0, "seriousNumAtRisk": 7, "otherNumAffected": 0, "otherNumAtRisk": 7}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Nocturnal asthma model is a very sensitive model, but very labor intensive and to get more completed subjects, we might need to do multicenter trial"}, "certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr.Sreekala Prabhakaran. Clinical Assistant Professor Pediatrics", "organization": "University of Florida", "email": "sprabhakaran@peds.ufl.edu", "phone": "352-273-8381"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001986", "term": "Bronchial Spasm"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "M5262", "name": "Bronchial Spasm", "asFound": "Bronchospasm", "relevance": "HIGH"}, {"id": "M15837", "name": "Spasm", "relevance": "LOW"}, {"id": "M12077", "name": "Muscle Cramp", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC05", "name": "Musculoskeletal Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M3767", "name": "Albuterol", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}